A Study of Cannabis Based Medicine Extracts and Placebo in Patients With Pain Due to Spinal Cord Injury

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
GW Pharmaceuticals Ltd.
ClinicalTrials.gov Identifier:
NCT01606202
First received: May 21, 2012
Last updated: August 28, 2012
Last verified: August 2012
  Purpose

A study to investigate the effects of sublingual cannabis based medicine extracts on neuropathic pain associated with spinal cord injury.


Condition Intervention Phase
Pain
Drug: GW-1000-02
Drug: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomised, Double Blind, Placebo Controlled, Parallel Group Comparative Study of the Efficacy, Safety and Tolerability of Sublingual Cannabis Based Medicine Extracts and Placebo in Patients With Intractable Neuropathic Pain Associated With Spinal Cord Injury

Resource links provided by NLM:


Further study details as provided by GW Pharmaceuticals Ltd.:

Primary Outcome Measures:
  • Change From Baseline in Mean Central Neuropathic Pain 11-Point Numerical Rating Scale Scores at the End of Treatment (up to 51 Days). [ Time Frame: Up to 51 days ] [ Designated as safety issue: No ]
    The Central Neuropathic Pain Numerical Rating Scale score was recorded three times daily, in the morning (on waking), at lunchtime and in the evening using the scale, 0 = 'No Pain' and 10 = 'Worst Possible Pain'. Patients were instructed to relate 'No Pain' to the time before the start of their spinal cord injury. End of Treatment was defined as the mean of the last seven days in the study or the mean of the last three days if the subject withdrew. A negative value indicates an improvement in pain score from baseline.


Secondary Outcome Measures:
  • Change From Baseline in the Mean Percentage of Days on Which Escape Medication Was Used at the End of Treatment [ Time Frame: Up to 51 days ] [ Designated as safety issue: No ]
    The percentage of days that subjects used escape medication was analysed and is presented as the mean change from baseline at the end of treatment. A negative value from baseline indicates an improvement.

  • Change From Baseline in Mean Spasm Severity Numerical Rating Scale Score at the End of Treatment [ Time Frame: Up to 51 days ] [ Designated as safety issue: No ]
    Each day, just before going to bed, patients recorded in their patient diary whether they experienced any spasms that day and, if yes, recorded the overall level of the spasm(s) experienced using an Numerical Rating Scale spasm scale ranging from 0 = "Mildest ever spasm" to 10 = "Worst ever spasm". The mean spasm severity scores were summarised and analysed analogously to the primary endpoint. A negative value from baseline indicates an improvement.

  • Change From Baseline in the Percentage of Days on Which Spasm Was Experienced at the End of Treatment [ Time Frame: Up to 51 days ] [ Designated as safety issue: No ]
    Each day, just before going to bed, patients recorded in their patient diary whether they experienced any spasms that day. The percentage of days on which spasm was experienced were summarised and analysed analogously to the primary endpoint. A negative value from baseline indicates an improvement.

  • Change From Baseline in Mean Spasticity Severity Numerical Rating Scale Scores the End of Treatment. [ Time Frame: 0 - 51 days ] [ Designated as safety issue: No ]
    Each day at bed time patients recorded whether they experienced any spasticity that day and, if yes, the overall level of spasticity experienced was quantified using an Numerical Rating Scale from 0 = "Mildest ever spasticity" to 10 = "Worst ever spasticity". The mean spasticity severity scores and the changes from baseline to End of Treatment were to be calculated. A negative value indicates an improvement from baseline.

  • Change From Baseline in the Percentage of Days on Which Spasticity Was Experienced at the End of Treatment [ Time Frame: Up to 51 days ] [ Designated as safety issue: No ]
    Each day, just before going to bed, patients recorded in their patient diary whether they had experienced any spasticity that day or not. The percentage of days on which spasticity was experienced (spasticity incidence) was calculated and summarised analogously to the primary efficacy parameter of Numerical Rating Scale pain score. A negative value from baseline indicates an improvement.

  • Change From Baseline in Modified Ashworth Scale Score at the End of Treatment [ Time Frame: Up to 51 days ] [ Designated as safety issue: No ]
    The Modified Ashworth Scale is a five-point scale conducted on four pre-identified muscle groups. Only the lower limb was assessed because not all Spinal Cord Injury patients upper limb disability. The assessor used the Modified Ashworth scale ranging from 0 ("No increase in muscle tone") to 4 ("Affected part(s) rigid in flexion or extension") to rate the muscle tone for knee and ankle for the left and right sides separately at a pre-dose visit and at the end of treatment. The average of the four individual scores and was taken. A negative value indicates an improvement from baseline.

  • Change From Baseline in the Mean Short Orientation Memory Function Concentration Test Score at the End of Treatment [ Time Frame: Up to 51 days ] [ Designated as safety issue: No ]

    Patients were asked at baseline and end of treatment, to complete the Short Orientation Memory Function Concentration Test as a measure of cognitive function. The minimum score is 0 and maximum of 28 which denoted good cognitive function .

    A negative value from baseline indicates a deterioration.


  • Change From Baseline in Mean Spitzer Quality of Life Index Score at the End of Treatment [ Time Frame: Up to 51 days ] [ Designated as safety issue: No ]
    The Spitzer Quality of Life Index questionnaire consists of five sections, relating to activity, daily living, health, support and outlook. Each section has three choices (numbered 1, 2 and 3) and the patient is required to choose the one that best describes their quality of life during the last week. Choice 1 is scored 2, choice 2 is scored 1 and choice 3 is scored 0. The total Spitzer is the unweighted sum of the five scores. The scale is 0 (bad) to 10 (good). A positive value indicates an improvement from baseline.

  • Change From Baseline in the Mean Caregiver Strain Index Score at the End of Treatment [ Time Frame: Up to 51 days ] [ Designated as safety issue: No ]
    Carers were asked at baseline and end of treatment to complete the Caregiver Strain Index, as a measure of the strain they felt from being a carer, the maximum possible score being 13. A negative value from baseline indicates an improvement.

  • Number of Subjects Who Reported an Improvement in Their Overall Condition in the Patient Global Impression of Change at the End of Treatment [ Time Frame: Up to 51 days ] [ Designated as safety issue: No ]
    The Patient Global Impression of Change asked patients to give their impression of the overall change in their condition during the study at the end of treatment using the following scale: 1 = Very Much Improved, 2 = Much Improved, 3 = Minimally Improved, 4 = No Change, 5 = Minimally Worse, 6 = Much Worse, 7 = Very Much Worse. The number of patients who scored their condition as 1, 2, or 3 (improved) is presented.

  • Change From Baseline in the Mean Brief Pain Inventory Score at the End of Treatment [ Time Frame: 0 - 51 days ] [ Designated as safety issue: No ]
    The Brief Pain Inventory is a 14-item questionnaire that asks patients to rate pain over the prior week and the degree to which it interferes with activities on a 0 to 10 scale, where 0=no pain and 10=pain as bad as you can imagine. Severity is measured as worst pain, least pain, average pain, and pain right now. The severity composite score is calculated as the arithmetic mean of the four severity items(range 0-10). A negative value indicates an improvement in worst pain score from baseline.

  • Change From Baseline in the Mean Sleep Disturbance Numerical Rating Scale Score at the End of Treatment [ Time Frame: 0 - 51 days ] [ Designated as safety issue: No ]
    Each day patients recorded in their patient diary whether they woke during the previous night using the following scoring system: 0 = No, 1 = Once, 2 = Twice, 3 = More than twice, 4 = Awake most of the night. A negative value indicates an improvement from baseline.

  • Incidence of Adverse Events as a Measure of Patient Safety. [ Time Frame: Up to 61 days ] [ Designated as safety issue: Yes ]
    The number of patients who experienced an adverse event during the study is presented.


Enrollment: 116
Study Start Date: July 2002
Study Completion Date: January 2005
Primary Completion Date: January 2005 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: GW-1000-02
Active treatment.
Drug: GW-1000-02
Contained delta-9-tetrahydrocannabinol (THC) (27 mg/ml):cannabidiol (CBD) (25 mg/ml) as extract of Cannabis sativa L., with peppermint oil, 0.05% (v/v), in ethanol:propylene glycol (50:50) excipient. Each actuation delivered 100 μl (THC 2.7 mg and CBD 2.5 mg). The maximum permitted dose of study medication was eight actuations in any three-hour period, and 48 actuations in any 24 hour period.
Other Name: Sativex
Placebo Comparator: Placebo
Placebo control.
Drug: Placebo
Contained peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient. Each actuation delivered 100 μl. The maximum permitted dose of study medication was eight actuations in any three-hour period, and 48 actuations in any 24 hour period.

Detailed Description:

This was a multi-centre, double-blind, randomised, placebo-controlled, parallel-group study to evaluate the efficacy and tolerability of GW-1000-02 in central neuropathic pain associated with spinal cord injury. Patients were screened to determine eligibility and completed a seven to 21 day baseline period. Patients then returned to the centre for assessment, randomisation and initial dosing. Visits occurred at the end of treatment week one and at the end of the study (treatment week three) or upon withdrawal. Throughout the study, patients were permitted to take paracetamol as escape analgesic to relieve breakthrough pain. Patients in this study could elect to be screened for an open label extension study of GW-1000-02.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Gave informed consent for participation in the study.
  • Male or Female, aged 18 years or above.
  • Diagnosis of non-acute spinal cord injury, with central neuropathic pain not wholly relieved by current therapy.
  • Central neuropathic pain with a mean severity Numerical Rating Scale score at least four during last seven days of the baseline period.
  • Relatively stable neurology during the preceding six months.
  • Stable medication regimen during the preceding four weeks.
  • Agreement, if female and of child bearing potential or if male with a partner of child bearing potential, to ensure that effective contraception was used during the study and for three months thereafter.
  • Had not used cannabinoids for at least the preceding seven days and willing to abstain from any use of cannabinoids during the study.
  • Clinically acceptable laboratory results at Visit 2.
  • Ability (in the investigator's opinion) and willingness to comply with all study requirements.
  • Agreement for the UK Home Office, their general practitioner, and their consultant if appropriate, to be notified of their participation in the study.

Exclusion Criteria:

  • History of schizophrenia, other psychotic illness, severe personality disorder or other significant psychiatric disorder other than depression associated with their underlying condition.
  • History of alcohol or substance abuse.
  • Severe cardiovascular disorder, such as ischaemic heart disease, arrhythmias (other than well controlled atrial fibrillation), poorly controlled hypertension or severe heart failure.
  • History of autonomic dysreflexia.
  • History of epilepsy.
  • If female, were pregnant or lactating, or were planning a pregnancy to occur during the course of the study.
  • Significant renal or hepatic impairment.
  • Elective surgery or other procedures requiring general anaesthesia scheduled to occur during the study.
  • Terminal illness or were considered inappropriate for placebo medication.
  • Any other significant disease or disorder which, in the opinion of the investigator, may have either put the subject at risk because of participation in the study, or may influenced the result of the study, or the subject's ability to participate in the study.
  • Regular levodopa therapy within the seven days leading to study entry.
  • If male, were receiving and were unwilling to stop sildenafil for the duration of the study.
  • Known or suspected hypersensitivity to cannabinoids or any of the excipients of the study medications.
  • Known or suspected adverse reaction to cannabinoids.
  • Intention to travel internationally during the study.
  • Intention to donate blood during the study.
  • Participation in another research study in the 12 weeks leading to study entry.
  • Previous randomisation into this study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01606202

Locations
United Kingdom
The Royal National Orthopaedic Hospital
Middlesex, United Kingdom, HA7 4LP
Sponsors and Collaborators
GW Pharmaceuticals Ltd.
Investigators
Principal Investigator: Jonathan Berman, BCh FRCA The Royal National Orthopaedic Hospital
  More Information

No publications provided

Responsible Party: GW Pharmaceuticals Ltd.
ClinicalTrials.gov Identifier: NCT01606202     History of Changes
Other Study ID Numbers: GWSC0101
Study First Received: May 21, 2012
Results First Received: July 19, 2012
Last Updated: August 28, 2012
Health Authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency
Romania: National Medicines Agency

Additional relevant MeSH terms:
Spinal Cord Injuries
Spinal Cord Diseases
Central Nervous System Diseases
Nervous System Diseases
Trauma, Nervous System
Wounds and Injuries

ClinicalTrials.gov processed this record on September 16, 2014